Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTPS1 | P17812 | 14/20 | 0.42 |
| ▸ | CTPS2 | Q9NRF8 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22490745 | 0.85 | CTPS1 (0.43) | CTPS1CTPS2GCK | |
| SCHEMBL21044071 | 0.85 | CTPS1 (0.43) | CTPS1CTPS2GCK | |
| SCHEMBL24088705 | 0.85 | CTPS1 (0.43) | CTPS1CTPS2TAAR1RAD52GCK | |
| SCHEMBL21044385 | 0.82 | CTPS1 (0.44) | CTPS1CTPS2GCK | |
| SCHEMBL24088651 | 0.82 | CTPS1 (0.42) | CTPS1CTPS2TAAR1GCK | |
| SCHEMBL24088711 | 0.81 | PTPRB (0.46) | CTPS1CTPS2 | |
| SCHEMBL25098788 | 0.79 | CTPS1 (0.42) | CTPS1CTPS2TAAR1 | |
| SCHEMBL22491753 | 0.78 | CTPS1 (0.45) | CTPS1CTPS2 | |
| SCHEMBL24088635 | 0.76 | CTPS1 (0.42) | CTPS1CTPS2GCK | |
| SCHEMBL21044563 | 0.76 | CTPS1 (0.43) | CTPS1CTPS2GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20210380575-A1 | COMPOUNDS | SYGNATURE DISCOVERY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| EP-3717465-A1 | COMPOUNDS | Step Pharma S.A.S. (FR) | 2020-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183229-A1 | Compounds | UGT1A1, CYP1A1, CYP1B1 | CTPS1 2556/4885CTPS2 2833/4885TAAR1 2266/4885 |
| US-20210380575-A1 | COMPOUNDS | UGT1A1, CYP1A1, CYP1B1 | CTPS1 2556/4885CTPS2 2833/4885TAAR1 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.